• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 28, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Study establishes new standard of care for pancreatic cancer patients

Bioengineer by Bioengineer
January 25, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A combination of two chemotherapy drugs – gemcitabine and capecitabine – should be the new standard of care for pancreatic cancer patients who have had surgery to remove their tumour, according to a Cancer Research UK-funded study published in The Lancet.

Experts say the combination should replace the standard treatment of giving patients gemcitabine alone following surgery.

Twenty-nine per cent of patients given the drug combination lived for at least five years compared with only 16 per cent of patients given gemcitabine alone.**

Peter Breaden, 67, a retired lab manager and grandfather of five from Merseyside, was diagnosed with pancreatic cancer in April 2010. Following surgery in May 2010 he was to start chemotherapy in the July and was offered the chance to take part in the ESPAC 4 trial. Peter said: "I know that new drugs and techniques need to be developed so when the doctors told me about the trial, there was no hesitation in my mind – I wanted to get involved.

"I was very grateful for the opportunity to contribute to this trial. For six months I had chemotherapy on three weekly cycles after my surgery. I am pleased to have been part of a trial that has been such a success. Research is absolutely essential and needs all our support."

The results, which were first presented at the American Society of Clinical Oncology (ASCO) in June 2016 but have now been peer-reviewed, show that this treatment plan is predicted to double the number of patients who survive their disease for at least five years.

Trial lead, Professor John Neoptolemos at the University of Liverpool, said: "This is one of the biggest ever breakthroughs prolonging survival for pancreatic cancer patients. When this combination becomes the new standard of care, it will give many patients living with the disease valuable months and even years. The difference in short term survival may seem modest, but improvement in long-term survival is substantial for this type of cancer."

This recommendation follows results from a clinical trial of 732 patients in hospitals across the UK, German, Sweden and France.

Around half of patients on the trial received gemcitabine and the other half received a combination of gemcitabine and capecitabine.

There was no significant difference in side effects*** between the patients on the standard treatment and the combination treatment.

This trial was set up in 2008 to address the poor pancreatic cancer survival rates.

The latest Cancer Research UK figures show that around 9,400 people are diagnosed with pancreatic cancer each year in the UK and around 8,800 people die**** from the disease each year.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: "Pancreatic cancer is a notoriously difficult disease to treat. Nearly 10,000 patients are diagnosed each year in the UK so we urgently needs new ways to treat and manage the disease.

"Research that tells us more about how the disease grows and spreads – and trials like this one – will be key to improve survival for patients living with the disease. There are still big leaps to be made, but Cancer Research UK is investing heavily into research to take on pancreatic cancer, and we are just starting to see the results."

###

For media enquiries please contact Fiona Dennehy in the Cancer Research UK press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.

Media Contact

Fiona Dennehy
[email protected]
020-346-98300
@CR_UK

http://www.cancerresearchuk.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

blank

Exploring Taar Expression in Mandarin Fish Response

October 28, 2025

New NR1H4 Mutation Causes Progressive Familial Cholestasis

October 27, 2025

LINC01198 Drives Vemurafenib Resistance via Hippo Pathway

October 27, 2025

CAP’s Role in Osteosarcoma’s Temperature Regulation Revealed

October 27, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1286 shares
    Share 514 Tweet 321
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    310 shares
    Share 124 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    197 shares
    Share 79 Tweet 49
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    135 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exploring Taar Expression in Mandarin Fish Response

New NR1H4 Mutation Causes Progressive Familial Cholestasis

LINC01198 Drives Vemurafenib Resistance via Hippo Pathway

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.